Chemistry:CST-3056
CST-3056, also known as CuraAX, is an α1A-adrenergic receptor agonist which is under development for the treatment of neurogenic orthostatic hypotension (nOH) (e.g. due to pure autonomic failure (PAF)), Parkinson's disease, and Alzheimer's disease.[1][2][3][4] It is taken orally.[1][3]
The drug is a centrally penetrant selective partial agonist of the α1A-adrenergic receptor.[3][4] nOH frequently occurs in neurodegenerative diseases like Parkinson's disease and Alzheimer's disease and CST-3056 is in part aimed to treat these cases, including to both stabilize blood pressure and improve cerebral perfusion (brain blood flow).[3][4]
CST-3056 is under development by CuraSen Therapeutics.[1][2][4] As of November 2025, it is in phase 2 clinical trials for treatment of orthostatic hypotension and the preclinical research stage of development for Alzheimer's disease.[1][2][4] The chemical structure of CST-3056 does not yet appear to have been disclosed.[1]
See also
- List of investigational orthostatic intolerance drugs
References
- ↑ 1.0 1.1 1.2 1.3 1.4 "CuraAX". AdisInsight. Springer Nature Switzerland AG. 19 November 2025. https://adisinsight.springer.com/drugs/800075875.
- ↑ 2.0 2.1 2.2 "Delving into the Latest Updates on CuraAX". Synapse. PatSnap. 18 September 2025. https://synapse.patsnap.com/drug/d7245b4bc8634ba7b60f84b5f60179b7.
- ↑ 3.0 3.1 3.2 3.3 "CST-3056". 30 December 2025. https://www.alzforum.org/therapeutics/cst-3056.
- ↑ 4.0 4.1 4.2 4.3 4.4 "CuraSen begins Phase IIa trial for neurogenic orthostatic hypotension". 24 October 2025. https://www.clinicaltrialsarena.com/news/curasen-phase-iia-trial-noh/.
 |  |
